Generative AI in Personalized Medicine Market (By Personalized Medicine Therapeutics: Pharmaceutical, Genomic Medicine, Devices; By Deployment Model: On-premise, Cloud Based; By End-User: Hospitals and Clinics, Clinical Research, Healthcare Organizations, Diagnostic Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Generative AI in Personalized Medicine Market 

5.1. COVID-19 Landscape: Generative AI in Personalized Medicine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Generative AI in Personalized Medicine Market, By Personalized Medicine Therapeutics

8.1. Generative AI in Personalized Medicine Market, by Personalized Medicine Therapeutics, 2023-2032

8.1.1 Pharmaceutical

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Genomic Medicine

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Devices

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Generative AI in Personalized Medicine Market, By Deployment Model

9.1. Generative AI in Personalized Medicine Market, by Deployment Model, 2023-2032

9.1.1. On-premise

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Cloud Based

9.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Generative AI in Personalized Medicine Market, By End-User 

10.1. Generative AI in Personalized Medicine Market, by End-User, 2023-2032

10.1.1. Hospitals and Clinics

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Clinical Research

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Healthcare Organizations

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Diagnostic Centers

10.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Generative AI in Personalized Medicine Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.1.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.1.3. Market Revenue and Forecast, by End-User (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.1.4.3. Market Revenue and Forecast, by End-User (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.1.5.3. Market Revenue and Forecast, by End-User (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.2.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.2.3. Market Revenue and Forecast, by End-User (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.2.4.3. Market Revenue and Forecast, by End-User (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.2.5.3. Market Revenue and Forecast, by End-User (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.2.6.3. Market Revenue and Forecast, by End-User (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.2.7.3. Market Revenue and Forecast, by End-User (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.3.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.3.3. Market Revenue and Forecast, by End-User (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.3.4.3. Market Revenue and Forecast, by End-User (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.3.5.3. Market Revenue and Forecast, by End-User (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.3.6.3. Market Revenue and Forecast, by End-User (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.3.7.3. Market Revenue and Forecast, by End-User (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.4.3. Market Revenue and Forecast, by End-User (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.4.4.3. Market Revenue and Forecast, by End-User (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.4.5.3. Market Revenue and Forecast, by End-User (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.4.6.3. Market Revenue and Forecast, by End-User (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.4.7.3. Market Revenue and Forecast, by End-User (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.5.3. Market Revenue and Forecast, by End-User (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.5.4.3. Market Revenue and Forecast, by End-User (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.5.5.3. Market Revenue and Forecast, by End-User (2020-2032)

Chapter 12. Company Profiles

12.1. Butterfly Network

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Deep Genomics

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Google LLC

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. IBM Watson Health

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Microsoft Corporation

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Aidoc

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Insilico Medicine

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. PathAI

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Tencent Holdings Ltd.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Neuralink Corporation

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample